Actively Recruiting
Austrian Biobanking Study for Sarcopenia
Led by Medical University of Graz · Updated on 2024-10-09
1000
Participants Needed
1
Research Sites
669 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical tests; biosamples to assess novel biomarker as well as advanced clinical assessments. In a small country like Austria, a nationwide biobanking study can enhance research enormously. The investigators therefore aim to extend the registry to all tertiary liver care centers in Austria in a second step.
CONDITIONS
Official Title
Austrian Biobanking Study for Sarcopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age >18 years
- Informed consent given
- CT or MRI scan performed as part of routine care within 2 months before or after the study visit
You will not qualify if you...
- Hepatic encephalopathy greater than grade 2 or other cognitive disorder preventing informed consent
- Hepatocellular carcinoma stage BCLC C or D
- Any condition or circumstance that the investigator believes would affect the patient's ability to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University of Graz
Graz, Austria, 8010
Actively Recruiting
Research Team
V
Vanessa Stadlbauer, MD
CONTACT
L
Lavra Celcer, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here